LC
XERS icon

Lindbrook Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Lindbrook Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$154 Buy
+28
New +$113 ﹤0.01% 2722

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lindbrook Capital's XERS Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2025: 28 shares worth $154. The stake represents ﹤0.01% of the portfolio and ranks #2722 among its holdings.

199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

  • Lindbrook Capital held 28 shares of Xeris Biopharma Holdings worth $154 as of Q1 2025.
  • Xeris Biopharma Holdings was a new Lindbrook Capital position in Q1 2025.
  • Xeris Biopharma Holdings made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2722 holding.
  • 199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.